X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ELX-02 (exaluren) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside. It is being evaluated for the treatment of nonsense mutation alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013, Eloxx’s lead TURBO-ZM based molecule, for the treatment of rare dermatological and other diseases associated with nonsense mutations.
Lead Product(s): ZKN-013
Therapeutic Area: Genetic Disease Product Name: ZKN-013
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: $473.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 13, 2024
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): ELX-02
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
The proceeds will advance ELX-02 (exaluren sulfate), being developed for the treatment of Alport syndrome with nonsense mutations and other rare proteinuric kidney diseases, progress the development of ZKN-013 and to fund discovery efforts for the company’s TURBO-ZM™ platform.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
ELX-02 exaluren) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Lead Product(s): Exaluren Sulfate,Ivacaftor
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Lead Product(s): ELX-02
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
ZKN-013 is a TURBO-ZM™ technology based molecule which allows rapid synthesis of novel oral ribosome modulating agents and has potential to fully unlock macrolide activity. It is being developed for recessive dystrophic epidermolysis bullosa with nonsense mutations.
Lead Product(s): ZKN-013
Therapeutic Area: Genetic Disease Product Name: ZKN-013
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
